S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

BioNxt Solutions Stock Price, News & Analysis (OTCMKTS:BNXTF)

$0.36
-0.01 (-2.68%)
(As of 12/1/2023 ET)
Compare
Today's Range
$0.36
▼
$0.36
50-Day Range
$0.00
▼
$0.43
52-Week Range
$0.00
▼
$0.58
Volume
100 shs
Average Volume
2,550 shs
Market Capitalization
$38.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartEarningsHeadlinesShort Interest

BNXTF stock logo

About BioNxt Solutions Stock (OTCMKTS:BNXTF)

BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, the United States, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

BNXTF Stock Price History

BNXTF Stock News Headlines

November 24, 2023 | benzinga.com
Bionxt Solutions Announces Convertible Debenture and Interest Settlement
November 20, 2023 | finanznachrichten.de
BioNxt Solutions Inc.: BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament
December 2, 2023 | DTI Trader (Ad)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
November 20, 2023 | finance.yahoo.com
BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament
November 16, 2023 | finanznachrichten.de
BioNxt Solutions Inc.: BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
November 15, 2023 | finance.yahoo.com
BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
November 13, 2023 | finance.yahoo.com
BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis
November 6, 2023 | benzinga.com
BioNxt Solutions berichtet über CPHI-Kongress in Barcelona
December 2, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
November 6, 2023 | finance.yahoo.com
BioNxt Solutions Reports on Barcelona CPHI Conference
October 27, 2023 | finanznachrichten.de
BioNxt Solutions Inc.: BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement
October 27, 2023 | finance.yahoo.com
BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement
October 3, 2023 | finanznachrichten.de
BioNxt Solutions Inc.: BioNxt Solutions Announces Change of Directors
October 3, 2023 | finance.yahoo.com
BioNxt Solutions Announces Change of Directors
September 28, 2023 | finanznachrichten.de
BioNxt Solutions Inc.: Bionxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement
September 28, 2023 | finance.yahoo.com
Bionxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement
August 28, 2023 | finance.yahoo.com
Bionxt Solutions Announces Closing of First Tranche of Non-Brokered Private Placement
August 7, 2023 | msn.com
BioNxt Solutions announces ~$4M private placement
August 4, 2023 | finanznachrichten.de
BioNxt Solutions Inc.: BioNxt Solutions Announces Non-Brokered Private Placement
August 2, 2023 | benzinga.com
BioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease
July 3, 2023 | finance.yahoo.com
BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson’s Disease
May 15, 2023 | benzinga.com
BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson's Disease
May 10, 2023 | investing.com
BioNxt Solutions Inc (BNXT)
May 10, 2023 | marketwatch.com
BioNxt Successfully Completes Pilot Study for Contract Development Customer
April 24, 2023 | marketwatch.com
BioNxt Secures Contract to Develop and Manufacture ODF Product for International Pharmaceutical Company
April 18, 2023 | msn.com
BioNxt buys state-of-the-art coating and cutting equipment to build out European commercial manufacturing capacity
April 17, 2023 | benzinga.com
BioNxt Acquires Commercial Coating and Cutting Equipment to Build Out European Commercial Manufacturing Capacity
See More Headlines
Receive BNXTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNxt Solutions and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BNXTF
CUSIP
N/A
CIK
N/A
Web
www.xphyto.com
Phone
780-818-6422
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-9,520,000.00
Net Margins
-2,508.06%
Pretax Margin
-3,142.48%
Return on Equity
N/A
Return on Assets
-277.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.70
Quick Ratio
0.70

Sales & Book Value

Annual Sales
$230,000.00
Price / Sales
166.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.03) per share
Price / Book
-12.08

Miscellaneous

Outstanding Shares
105,940,000
Free Float
N/A
Market Cap
$38.40 million
Optionable
Not Optionable
Beta
0.92
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Hugh A. D. Rogers B.Sc. (Age 43)
    LL.B, President, CEO & Director
    Comp: $175.55k
  • Mr. Patrick Joseph Meagher C.A. (Age 37)
    C.P.A., CA, CPA, CFO & Director
    Comp: $52.57k
  • Dr. Florian A. Sahr
    Head of Project Management

Key Competitors

View All Competitors














BNXTF Stock Analysis - Frequently Asked Questions

How have BNXTF shares performed in 2023?

BioNxt Solutions' stock was trading at $0.3880 at the beginning of 2023. Since then, BNXTF stock has decreased by 6.6% and is now trading at $0.3625.
View the best growth stocks for 2023 here.

Are investors shorting BioNxt Solutions?

BioNxt Solutions saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 1,800 shares, an increase of 80.0% from the October 31st total of 1,000 shares. Based on an average daily volume of 3,200 shares, the short-interest ratio is presently 0.6 days.
View BioNxt Solutions' Short Interest.

How do I buy shares of BioNxt Solutions?

Shares of BNXTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:BNXTF) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -